Free Trial

Grail Q3 2024 Earnings Report

Grail logo
$31.20 -0.93 (-2.89%)
As of 03/25/2025 04:00 PM Eastern

Grail EPS Results

Actual EPS
-$3.94
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Grail Revenue Results

Actual Revenue
$28.65 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Grail Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Remove Ads

Grail Earnings Headlines

Grail price target raised to $20 from $16 at Morgan Stanley
Trump’s Final Plan
Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.
Why Grail (GRAL) Is Falling Today
See More Grail Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Grail? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grail and other key companies, straight to your email.

About Grail

Grail (NASDAQ:GRAL) is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.

View Grail Profile

More Earnings Resources from MarketBeat